Everolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinoma

[1]  R. Echols,et al.  in a Phase 2 Study , 2019 .

[2]  Nicholas J. Vogelzang,et al.  Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma: Updated Results From a Phase 1/2 Open-label Study , 2017, JAMA oncology.

[3]  J. Bellmunt,et al.  Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives , 2017, Drugs.

[4]  A. Ravaud,et al.  Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Plimack,et al.  Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. , 2017, The Lancet. Oncology.

[6]  S. Culine,et al.  Pembrolizumab as Second‐Line Therapy for Advanced Urothelial Carcinoma , 2017, The New England journal of medicine.

[7]  Marian Harris,et al.  Institutional implementation of clinical tumor profiling on an unselected cancer population. , 2016, JCI insight.

[8]  B. Gornicka,et al.  Role of angiogenesis in urothelial bladder carcinoma , 2016, Central European journal of urology.

[9]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[10]  Y. Yen,et al.  Trichlorobenzene-substituted azaaryl compounds as novel FGFR inhibitors exhibiting potent antitumor activity in bladder cancer cells in vitro and in vivo , 2016, Oncotarget.

[11]  P. Stephens,et al.  Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations , 2016, Cancer.

[12]  A. N. Meyer,et al.  Oncogenic Gene Fusion FGFR3-TACC3 Is Regulated by Tyrosine Phosphorylation , 2016, Molecular Cancer Research.

[13]  A. Martelli,et al.  The PI3K/Akt/mTOR Pathway , 2016 .

[14]  Siraj M. Ali,et al.  Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and Amplification. , 2015, European urology.

[15]  R. Kurzrock,et al.  Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy , 2015, Investigational New Drugs.

[16]  D. Proia,et al.  FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism , 2014, Molecular Cancer Research.

[17]  S. Gabriel,et al.  Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. , 2014, Cancer discovery.

[18]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[19]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[20]  Nickolay A. Khazanov,et al.  Identification of targetable FGFR gene fusions in diverse cancers. , 2013, Cancer discovery.

[21]  Levi A Garraway,et al.  Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Knowles,et al.  Oncogenic FGFR3 gene fusions in bladder cancer , 2012, Human molecular genetics.

[23]  C. Sander,et al.  Genome Sequencing Identifies a Basis for Everolimus Sensitivity , 2012, Science.

[24]  Bruce E. Johnson,et al.  Everolimus and Erlotinib as Second- or Third-Line Therapy in Patients with Advanced Non–Small-Cell Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[25]  Jorge A. Garcia,et al.  Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder. , 2012, Seminars in oncology.

[26]  K. Pointon,et al.  Sirolimus Therapy for Angiomyolipoma in Tuberous Sclerosis and Sporadic Lymphangioleiomyomatosis: A Phase 2 Trial , 2011, Clinical Cancer Research.

[27]  M. Höglund,et al.  A Systematic Study of Gene Mutations in Urothelial Carcinoma; Inactivating Mutations in TSC2 and PIK3R1 , 2011, PloS one.

[28]  D. Richel,et al.  mTOR inhibitor treatment of pancreatic cancer in a patient With Peutz-Jeghers syndrome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Fimmers,et al.  Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[30]  R. Fimmers,et al.  Randomized phase III trial of 2 nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer : short-term versus prolonged treatment , 2011 .

[31]  C. Ching,et al.  Expanding therapeutic targets in bladder cancer: the PI3K/Akt/mTOR pathway , 2010, Laboratory Investigation.

[32]  N. Turner,et al.  Fibroblast growth factor signalling: from development to cancer , 2010, Nature Reviews Cancer.

[33]  T. Ichikawa,et al.  Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. , 2009, Japanese journal of clinical oncology.

[34]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[35]  D. Jonas,et al.  Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells , 2009, BMC Cancer.

[36]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[37]  J. LoPiccolo,et al.  Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[38]  Vincent J Schmithorst,et al.  Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. , 2008, The New England journal of medicine.

[39]  Y. Sugimura,et al.  Paclitaxel Carboplatin chemotherapy as a second‐line chemotherapy for advanced platinum resistant urothelial cancer in Japanese cases , 2007, International journal of urology : official journal of the Japanese Urological Association.

[40]  Y. Tsai,et al.  Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: a phase II study , 2007, Anti-cancer drugs.

[41]  H. Koeffler,et al.  Effect of SU11248 on gastrointestinal stromal tumor‐T1 cells: Enhancement of growth inhibition via inhibition of 3‐kinase/Akt/mammalian target of rapamycin signaling , 2006, Cancer science.

[42]  H. Lane,et al.  Differential anti-vascular effects of mTOR or VEGFR pathway inhibition: A rational basis for combining RAD001 and PTK787/ZK222584 , 2005 .

[43]  J. Baselga,et al.  Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer , 2002, Cancer investigation.

[44]  S. Krege,et al.  Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study. , 2001, The Journal of urology.

[45]  H. Niitani,et al.  [Phase II study]. , 1995, Gan to kagaku ryoho. Cancer & chemotherapy.

[46]  H. S. Greene.  On the development of cancer. , 1948, Scientific American.